Caladrius Biosciences (CLBS) Gets a Buy Rating from H.C. Wainwright


In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Caladrius Biosciences (NASDAQ: CLBS), with a price target of $15. The company’s shares closed on Friday at $5.47.

Selvaraju said:

“Our price target is derived from a market value of the firm at $150M vs. the prior $120M as our discounted cash flow (DCF) analysis has been rolled forward to the present date. The valuation assessment comprises a DCF asset value for 1 diabetes and CD34+ cell therapy in refractory angina, with a 15% discount rate and 0% terminal growth rate. Probabilities of success are 20% for CD34+, respectively.”

According to TipRanks.com, Selvaraju is a 4-star analyst with an average return of 3.6% and a 47.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

Currently, the analyst consensus on Caladrius Biosciences is a Moderate Buy with an average price target of $15.

See today’s analyst top recommended stocks >>

The company has a one-year high of $11.65 and a one-year low of $2.63. Currently, Caladrius Biosciences has an average volume of 324.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Caladrius Biosciences, Inc. operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts